课题基金 / 基金详情

The relationship between disease progression and chemoresistance mediated by plasma gelsolin in epithelial ovarian cancer

The relationship between disease progression and chemoresistance mediated by plasma gelsolin in epithelial ovarian cancer
上皮性卵巢癌血浆凝溶胶蛋白介导的疾病进展与化疗耐药的关系
批准号:
476288
负责人:
Gerber Emma
金额:
$7.65万
依托单位国家:
加拿大
项目类别:
Studentship Programs
财政年份:
2022
资助国家:
加拿大
项目状态:
未结题
起止时间:
2022-11-01 至 2025-11-01

项目摘要

项目成果

Gerber Emma的其他基金

相似基金

相关文献

中文摘要
翻译
上皮性卵巢癌(EOC)是最致命的妇科癌症,由于诊断在晚期疾病和耐药治疗。先前的研究表明,血浆凝溶胶蛋白(pGSN)是一种在EOC化学代谢中起重要作用的蛋白质。
英文摘要
Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer due to diagnosis in advanced-stage disease and resistance to treatment. Previous work has shown that plasma gelsolin (pGSN) is a protein that plays an important role in EOC chemoresis
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Combination of plasma gelsolin with radiological imaging for prognostication of ovarian cancer
  • 批准号:
    495885
  • 项目类别:
    Miscellaneous Programs
  • 资助金额:
    $0.44万
  • 财政年份:
    2023
  • 负责人:
    Gerber Emma
  • 依托单位:
Exploring the use of exosomal plasma gelsolin as a biomarker for early ovarian cancer diagnosis
  • 批准号:
    467118
  • 项目类别:
    Studentship Programs
  • 资助金额:
    $1.27万
  • 财政年份:
    2021
  • 负责人:
    Gerber Emma
  • 依托单位:
海外基金